Loxapine inhibits replication of hepatitis A virus in vitro and in vivo by targeting viral protein 2C

• Published in: PLoS pathogens Vol. 20; no. 3; p. e1012091
• Main Authors: Matsuda, Mami, Hirai-Yuki, Asuka, Kotani, Osamu, Kataoka, Michiyo, Zheng, Xin, Yamane, Daisuke, Yokoyama, Masaru, Ishii, Koji, Muramatsu, Masamichi, Suzuki, Ryosuke
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 13.03.2024; Public Library of Science (PLoS)
• Subjects: Analysis; Animals; Antiviral agents; Antiviral drugs; Biological response modifiers; Biology and life sciences; Care and treatment; Cytotoxicity; Dengue fever; Diagnosis; Dopamine; Dopamine D2 receptors; Dosage and administration; Drug development; Drugs; Food contamination & poisoning; Genomes; Genotype & phenotype; Health aspects; Hepatitis; Hepatitis A; Hepatitis A virus; Hepatitis A virus - genetics; Hepatitis A virus - metabolism; Hepatitis C; Infection; Internal ribosome entry site; Loxapine; Medical research; Medicine and health sciences; Medicine, Experimental; Methicillin; Mice; Molecular dynamics; Mutation; Phenothiazine; Physical Sciences; Protein 2C; Protein Biosynthesis; Proteins; Receptors; Replication; Research and Analysis Methods; Ribonucleic acid; RNA; RNA - metabolism; RNA polymerase; RNA, Viral - genetics; RNA, Viral - metabolism; Schizophrenia; Staphylococcus infections; Viral proteins; Viral Proteins - metabolism; Virus Replication - genetics; Viruses; Japan; United States > US

No antiviral drugs currently are available for treatment of infection by hepatitis A virus (HAV), a causative agent of acute hepatitis, a potentially life-threatening disease. Chemical screening of a small-compound library using nanoluciferase-expressing HAV identified loxapine succinate, a selectiv...